» Articles » PMID: 3080477

Structural Analysis and Immunogenicity of Pseudomonas Aeruginosa Immunotype 2 High Molecular Weight Polysaccharide

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1986 Feb 1
PMID 3080477
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed high molecular weight polysaccharide (PS) from the Fisher immunotype 2 (IT-2) strain of Pseudomonas aeruginosa for molecular composition and structure, then determined its immunogenicity in healthy adults. The PS was composed of 2-acetamido-2,6-dideoxygalactose (N-acetyl fucosamine) and glucose in a molar ratio of 2:1. Structural analysis by carbon-13 and proton nuclear magnetic resonance confirmed that the high molecular weight PS was structurally identical to that of the O-specific side chain of the lipopolysaccharide. PS differed from this material in molecular size. Immunization of 19 adult volunteers with doses of 50-100 micrograms of PS resulted in significant rises (P less than 0.04-P less than 0.0001) in binding antibody levels and killing antibody titers 2 and 4 wk postimmunization. The only reaction to the vaccine was localized tenderness at the immunization site. Analysis of the immunoglobulin isotype response to the vaccine showed a rise in specific serum IgG and IgA antibodies. Heterologous responses to other P. aeruginosa PS antigens were not seen. The antibody levels attained by vaccination were comparable with those in acute-phase serum samples of patients who survived sepsis with IT-2 P. aeruginosa and were significantly higher (P less than 0.03) than specific antibody levels in bacteremic patients who died. These results confirm that PS is a high molecular weight, immunogenic form of the P. aeruginosa IT-2 serotype antigen, eliciting levels of type-specific antibody comparable with those seen among patients surviving an episode of P. aeruginosa sepsis.

Citing Articles

Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.

Hatano K, Pier G Infect Immun. 1998; 66(8):3719-26.

PMID: 9673254 PMC: 108407. DOI: 10.1128/IAI.66.8.3719-3726.1998.


Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Pittet J, Matthay M, Pier G, Grady M, Wiener-Kronish J J Clin Invest. 1993; 92(3):1221-8.

PMID: 8376581 PMC: 288261. DOI: 10.1172/JCI116693.


Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Pier G, Koles N, Meluleni G, Hatano K, Pollack M Infect Immun. 1994; 62(4):1137-43.

PMID: 8132318 PMC: 186240. DOI: 10.1128/iai.62.4.1137-1143.1994.


Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Johansen H, Espersen F, Cryz Jr S, Hougen H, Fomsgaard A, Rygaard J Infect Immun. 1994; 62(8):3146-55.

PMID: 8039883 PMC: 302939. DOI: 10.1128/iai.62.8.3146-3155.1994.


Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Hatano K, Boisot S, Desjardins D, Wright D, Brisker J, Pier G Infect Immun. 1994; 62(9):3608-16.

PMID: 7520416 PMC: 303009. DOI: 10.1128/iai.62.9.3608-3616.1994.


References
1.
Jones R, Roe E, Gupta J . Controlled trials of a polyvalent pseudomonas vaccine in burns. Lancet. 1979; 2(8150):977-82. DOI: 10.1016/s0140-6736(79)92559-5. View

2.
Crowder J, Fisher M, White A . Type-specific immunity in pseudomonas diseases. J Lab Clin Med. 1972; 79(1):47-54. View

3.
Pollack M . Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983; 147(6):1090-8. DOI: 10.1093/infdis/147.6.1090. View

4.
Pollack M, Young L . Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979; 63(2):276-86. PMC: 371950. DOI: 10.1172/JCI109300. View

5.
Pennington J . Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis. J Infect Dis. 1974; 130 Suppl(0):S159-62. DOI: 10.1093/infdis/130.supplement.s159. View